Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics

Saivenkat Vagvala; Jeffrey P Guenette; Camilo Jaimes; Raymond Y Huang

doi:10.1186/s40644-022-00455-5

Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics

Cancer Imaging. 2022 Apr 18;22(1):19. doi: 10.1186/s40644-022-00455-5.

Authors

Saivenkat Vagvala¹, Jeffrey P Guenette¹, Camilo Jaimes², Raymond Y Huang³

Affiliations

¹ Division of Neuroradiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, 75 Francis St, Boston, MA, 02115, USA.
² Division of Neuroradiology, Boston Children's, 300 Longwood Ave., 2nd floor, Main Building, Boston, MA, 02115, USA.
³ Division of Neuroradiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, 75 Francis St, Boston, MA, 02115, USA. ryhuang@bwh.harvard.edu.

Abstract

Currently, most CNS tumors require tissue sampling to discern their molecular/genomic landscape. However, growing research has shown the powerful role imaging can play in non-invasively and accurately detecting the molecular signature of these tumors. The overarching theme of this review article is to provide neuroradiologists and neurooncologists with a framework of several important molecular markers, their associated imaging features and the accuracy of those features. A particular emphasis is placed on those tumors and mutations that have specific or promising imaging correlates as well as their respective therapeutic potentials.

Keywords: 1p19q; BRAF; EGFR; FGFR3-TACC3; Glioma; H3 K27-altered; IDH; Medulloblastoma; TERT.

Publication types

Review

MeSH terms

Brain Neoplasms* / diagnostic imaging
Brain Neoplasms* / genetics
Brain Neoplasms* / therapy
Diagnostic Imaging
Glioma* / genetics
Humans
Mutation